Schizophrenia. Schizophrenia, unspecified
Conditions
Interventions
Intervention 1: Intervention group: Under treatment with citalopram (up to 40 milligrams per day) and olanzapine (dose of 15 milligrams). Intervention 2: Intervention group: Under treatment with Cital
Sponsors
Alborz University of Medical Science
Eligibility
Sex/Gender
All
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: Patients who, based on criteria, have been diagnosed with schizophrenia and are receiving treatment by a psychiatrist in a psychiatric ward up to 3 years after diagnosis. The minimum PANSS score should be 60 in. This score requires a minimum of 20 on the negative symptom subscale and a BPRS score of 41. The age range of participants is between 18 and 50.
Exclusion criteria
Exclusion criteria: The tendency and decision towards suicide in the Hamilton test. The tendency and decision towards suicide in the Hamilton test. Individuals with a score greater than 14 based on the 17-item Hamilton Depression Rating Scale (HDRS), or meeting major depression criteria, or having a score of above 4 on all but the depression item of the PANAS. Patients diagnosed with any type of non-schizophrenic mental disorder, especially bipolar disorder, schizoaffective disorder, and individuals with major depressive disorders that have been identified by a psychiatric interview. In addition, patients who have received electroconvulsive therapy (ECT) in the past 2 weeks are not eligible to participate in this study. Any serious or neurological medical condition, pregnancy or lactation, pregnant women without contraception, patients with Class IV and III heart failure, drug or insulin-dependent diabetes, liver disease, or congestive heart failure are not eligible for the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Negative symptoms in patients with chronic schizophrenia. Timepoint: In this study, negative symptoms of schizophrenia will be assessed in the beginning, 4th week and at the end of the 8th week of the clinical trial. Method of measurement: The PANSS-BPRS questionnaire and the Hamilton questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| Positive symptoms of patient with chronic schizophrenia. Timepoint: In this study, negative symptoms of schizophrenia will be assessed in the beginning, 4th week and at the end of the 8th week of the clinical trial. Method of measurement: Diagnosis based on DSM-5 criteria, PANSS-BPRS questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSaeideh Mahmoudnia
Alborz university of medical sciences
Outcome results
None listed